What is the best approach for withdrawing from Adderall (amphetamine and dextroamphetamine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Approach for Adderall Withdrawal

The best approach for withdrawing from Adderall (amphetamine and dextroamphetamine) is to implement a gradual tapering schedule in a supportive environment with symptomatic management of withdrawal symptoms, rather than abrupt discontinuation. 1, 2

Understanding Adderall Withdrawal

  • Abrupt cessation of Adderall after prolonged high-dose administration results in extreme fatigue, mental depression, and changes in sleep EEG patterns 1
  • Withdrawal from amphetamines is best undertaken in a supportive environment, with symptoms including hyperactivity, hyperthermia, tachycardia, tachypnea, mydriasis, tremors, and potentially seizures 3, 2
  • Intense craving during withdrawal may be a critical factor leading to relapse to amphetamine use 2

Recommended Tapering Protocol

Gradual Dose Reduction

  • Implement a gradual tapering schedule rather than abrupt discontinuation to minimize withdrawal symptoms 4
  • Consider a hyperbolic tapering approach (exponential dose reduction) which appears to be the most promising strategy for psychiatric drug discontinuation 5
  • Reduce dose by approximately 25% every 1-2 weeks, similar to the approach used for benzodiazepines 4

Supportive Environment

  • Withdrawal should be conducted in a supportive environment with regular monitoring 4
  • For patients with severe dependence or comorbidities, consider inpatient management 4

Management of Withdrawal Symptoms

Symptomatic Treatment

  • Relief of symptoms such as agitation and sleep disturbance may be achieved with symptomatic medication during the withdrawal period 4
  • For severe anxiety or agitation, short-term symptomatic medications may be considered 4
  • Monitor for less common but serious withdrawal effects such as depression or psychosis; if these occur, the individual needs close monitoring and specialist consultation 4

Psychosocial Support

  • Provide short-duration psychosocial support modeled on motivational principles 4
  • Consider cognitive-behavioral therapy to increase tapering success rates, similar to its effectiveness in benzodiazepine tapering 4
  • Brief interventions should incorporate individualized feedback and advice on reducing or stopping stimulant consumption 4

Monitoring and Follow-up

  • Regular follow-up is essential to monitor withdrawal symptoms and provide support 4
  • Monitor for potential complications including severe withdrawal symptoms, depression, or psychosis 4
  • Offer continued follow-up after successful discontinuation to prevent relapse 4

Special Considerations

  • For patients with severe dependence or those who do not respond to initial withdrawal management, consider referral for specialist assessment 4
  • Be aware that tolerance, extreme psychological dependence, and severe social disability can occur with amphetamine abuse 1
  • The most severe manifestation of chronic intoxication is psychosis, which can be clinically indistinguishable from schizophrenia (though rare with oral amphetamines) 1

Common Pitfalls to Avoid

  • Avoid abrupt discontinuation, which can worsen withdrawal symptoms and increase risk of relapse 1, 2
  • Do not use dexamphetamine as a treatment for stimulant use disorders during withdrawal 4
  • Be cautious about potential misdiagnosis of withdrawal symptoms as recurrence of underlying conditions (similar to what happens with SSRI withdrawal) 6
  • Recognize that current guidelines often lack standardization for psychiatric drug discontinuation, making safe withdrawal challenging 5

References

Research

Treatment for amphetamine withdrawal.

The Cochrane database of systematic reviews, 2009

Research

Adderall® (amphetamine-dextroamphetamine) toxicity.

Topics in companion animal medicine, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.